Showing 2061-2070 of 4944 results for "".
- Aveeno Launches #SkinVisibility Campaignhttps://practicaldermatology.com/news/aveeno-launches-skinvisibility-campaign/2460948/Aveeno’s new #SkinVisibility campaign aims to address the underdiagnosis, care and treatment of eczema on Black skin. The campaign, which launches during Eczema Awareness Month, underscores the brand's pledge to help 100,000 people with eczema find relief&n
- Long-term Extension Study Confirms Benefits of Topical Tapinarof in Psoriasishttps://practicaldermatology.com/news/long-term-extension-study-confirms-benefits-of-topical-tapinarof-in-ad/2460936/Final results from the Phase 3 PSOARING 3 long-term extension study show that Dermavant’s investigational tapinarof 1%, once daily, non-steroidal topical cream for the treatment of plaque psoriasis in adults was well tolerated long term, with a safety
- Garnier Launches New Green Beauty Campaignhttps://practicaldermatology.com/news/garnier-launches-new-green-beauty-campaign/2460931/Garnier is launching a new educational campaign on how to live a greener life with content produced by National Geographic CreativeWorks. The series, which will premiere at Expo 2020 Dubai and roll out worldwide, aims to share expert knowledge and real-world advice on key sustainability
- Bimekizumab Performs Well in Psoriasis with Results Lasting through Two Yearshttps://practicaldermatology.com/news/bimekizumab-performs-well-in-psoriasis-with-results-lasting-through-two-years/2460929/Interim results from the BE BRIGHT open-label extension (OLE) study showed clinical responses observed in bimekizumab-treated psoriasis patients during the first 16 weeks of BE SURE were sustained through to two years of treatment with continuous maintenance dosing, UCB reports. T
- Cetaphil Updates Formulas, Launches 16 New Productshttps://practicaldermatology.com/news/cetaphil-updates-formulas-launches-16-new-products/2460922/Cetaphil is updating their formulas and launching 16 new products including their first-ever acne care line. The brand’s most prominent products have been upgraded to feature a blend of Niacinamide (Vitamin B3), Panthenol (Vitamin B5), and hydrating Glycerin to improve skin’
- Mayne Pharma's Lexette Approved for Adolescentshttps://practicaldermatology.com/news/mayne-pharmas-lexette-approved-for-adolescents/2460921/Lexette® (halobetasol propionate) foam, 0.05% from Mayne Pharma is now approved for the treatment of plaque psoriasis in patients aged 12 years and older. FDA approved Lexette in 2018 for use in adults. Approval in adolescents is
- Study Highlights Severe AD, Depression Linkhttps://practicaldermatology.com/news/study-highlights-severe-ad-depression-link/2460907/Severe atopic dermatitis (AD) travels with depression, a new study shows. In a study of 11, 181 kids, severe AD was associated with an approximately 2-fold increase in the likelihood of symptoms of depression and internalizing symptoms across childhood, compared to eczema-free kids.&nbs
- Landmarks and Bridges Go Blue for Alopecia Areata Awareness Monthhttps://practicaldermatology.com/news/landmarks-and-bridges-go-blue-for-alopecia-areata-awareness-month/2460900/Bridges, buildings and other landmarks across the United States will be illuminated blue in recognition of Alopecia Areata Awareness Month this September, The current illumination schedule follows below. Any updates or additions to the schedule will be posted
- Lilly's Lebrikizumab Performs Well in Two Phase 3 AD Trialshttps://practicaldermatology.com/news/lillys-lebrikizumab-performs-well-in-two-phase-3-ad-trials/2460892/Eli Lilly and Company's lebrikizumab led to significant improvements with at least 75 percent skin clearance in more than half of people with moderate-to-severe atopic dermatitis (AD), according to top-line results from ADvocate 1 and ADvocate 2. All primary and all key secondary en
- MoonLake Immunotherapeutics Taps Former Kymab CEO Simon Sturge as Chairman and Spike Loy for the Board of Directorshttps://practicaldermatology.com/news/moonlake-immunotherapeutics-taps-former-kymab-ceo-simon-sturge-as-chairman-and-spike-loy-for-the-board-of-directors/2460887/Simon Sturge is the new Chairman of MoonLake Immunotherapeutics AG, and Spike Loy has joined the Company’s Board of Directors. Mr. Sturge has 40 years of international leadership experience in the biotechnology and pharmaceutical industry. Most recently, he was Chief Ex